2024 New York Oncology Forum

Saturday, October 5, 2024, 8:00 am – 5:00 pm

Sunday, October 6, 2024, 8:30 am – 12:00 pm

Sheraton LaGuardia East • 135-20 39th Ave • Queens, NY 11354

CAHON

New York Oncology Forum

2024 Corporate Partners

Lilly

NOVARTIS

2024 Annual Oncology Supporters

AstraZeneca

BeiGene

janssen | PHARMACEUTICAL COMPANIES OF Johnson & Johnson

rigel

sanofi

Bronze Sponsor

Coherus

EXELIXIS

Takeda

Exhibitors

agios

astellas

Boehringer Ingelheim

Daiichi-Sankyo

Genentech
A Member of the Roche Group

Genmab

GSK

Incyte

IPSEN

Jazz Pharmaceuticals

MERCK

NOVARTIS

Pfizer Oncology

PharmaEssentia

REGENERON

sanofi

SERVIER

sobi
rare strength

MENARINI group

Stemline

The RESULTS speak for themselves

What do they mean
for your patients?

Visit the Novartis booth to discover the impact

Explore the KISQALI difference

NOVARTIS

KISQALI® ribociclib 200 mg tablets

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

Printed in USA 2/24 414621

Verzenio®
abemaciclib
50 | 100 | 150 | 200 mg tablets

FIND THE SUPPORT YOUR PATIENTS NEED WITH VERZENIO

Access resources at Verzenio.com

Lilly

CONTENTS

ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

CAHON MEMBERSHIP

Apply to become a CAHON Member at cahon.org

Value of a CAHON Membership

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

MEMBERSHIP CATEGORIES

Regular/Active Membership
Associate Membership
Allied Membership

Visit cahon.org/membership for more information on membership.

SAVE THE DATES!

Winter Symposium and Reception
Friday, December 6, 2024
University Club Atop Symphony Tower
San Diego, CA

Community Oncology Forum
Saturday, March 29, 2025
MGM National Harbor
National Harbor, MD

Summer Symposium and Reception
Saturday, May 31, 2025
The Metropolitan Club at Willis Tower
Chicago, IL

Program

SATURDAY, OCTOBER 5, 2024, 8:00 AM – 5:00 PM

7:30 – 9:00 am	**On-site Registration, Exhibitors Visitation**
8:00 – 9:00 am	**Breakfast Promotional Talk** - *Sponsored by Coherus* Advances in the Treatment of Recurrent Locally Advanced/Metastatic (R/M) Nasopharyngeal Carcinoma (NPC) with LOQTORZI® (toripalimab-tpzi) Speaker: Zujun Li, MD – *NYU Langone Health* Moderator: Yue Zhang, MD – *Virginia Oncology Associates*
9:00 – 10:40 am	**Plenary Session I – Part I** Session Chairs: Liang Deng, MD, PhD – *CAHON President, Memorial Sloan Kettering Cancer Center* Jing-Zhou Hou, MD, PhD – *CAHON Board Chair, University of Pittsburgh Medical Center*
9:00 – 9:05 am	**Welcome Remarks** Delong Liu, MD, PhD – *New York Medical College*
9:05 – 9:15 am	**Introduction of Lifetime Achievement Award recipient** Jing-Zhou Hou, MD, PhD – *CAHON Board Chair, University of Pittsburgh Medical Center*
9:15 – 9:40 am	**Lifetime Achievement Award Lecture** Lillian L. Siu, MD, FRCPC, FAACR, FASCO – *Princess Margaret Cancer Centre*
9:40 – 10:20 am	**New Agents and Regimens for Upper GI Cancer** Speaker: David Ilson, MD, PhD – *Memorial Sloan Kettering Cancer Center* Moderator: Weijing Sun, MD, FACP – *University of Kansas Medical Center*
10:20 – 10:40 am	**Break and Visit Exhibitors**
10:40 am – 12:00 pm	**Plenary Session I – Part II** Session Chair: Minggui Pan, MD, PhD – *Stanford University*
10:40 – 11:20 am	**Current and Future Therapies for Multiple Myeloma** Speaker: Paul Richardson, MD – *Dana-Farber Cancer Institute* Moderator: J. Christine Ye, MD, MS – *MD Anderson Cancer Center*
11:20 am – 12:00 pm	**Current and Future Directions of CAR T Therapy for Hematological Malignancies** Speaker: Yi Lin, MD, PhD – *Mayo Clinic, Rochester, MN* Moderator: Hongtao Liu, MD, PhD – *University of Wisconsin at Madison*
12:00 – 1:00 pm	**Lunch Promotional Talk** –*Sponsored by Novartis* Addressing the Needs of Patients Across the HR+/HER2- Landscape: The Role of KISQALI in eBC and mBC Moderator: Wanqing Iris Zhi, MD, PhD – *Memorial Sloan Kettering Cancer Center*
1:00 – 1:20 pm	**Break and Visit Exhibitors**
1:20 – 2:40 pm	**Plenary Session II** Session Chair: Aiwu Ruth He, MD, PhD – *Georgetown University*
1:20 – 2:00 pm	**New Agents and Regimens for Small Cell Lung Cancer** Speaker: Kai He, MD, PhD – *The Ohio State University* Moderator: Ligeng Tian, MD, PhD – *Virginia Oncology Associates*
2:00 – 2:40 pm	**Novel Therapy for HER2 positive and HER2 low Breast Cancer** Speaker: Yuan Yuan, MD, PhD – *Cedars Sinai Medical Center* Moderator: Cynthia Ma, MD, PhD – *Washington University*
2:40 – 3:00 pm	**Break and Visit Exhibitors**
3:00 – 3:40 pm	**Plenary Session III** Session Chair: Yi Feng, MD, PhD – *Tennessee Cancer Specialists*
3:00 – 3:40 pm	**Radioligand therapy: Prostate Cancer's Newest Treatment Modality** Speaker: Michael Morris, MD, FASCO – *Memorial Sloan Kettering Cancer Center* Moderator: Jingsong Zhang, MD, PhD – *H Lee Moffitt Cancer Center*

Program

3:40 – 4:00 pm **Break and Visit Exhibitors**

4:00 – 5:00 pm **Case Presentations - Clinical Hematology/Oncology Session**

Session Chair: Shuang Fu, MD, PhD – *Jackson Hematology Oncology*

Moderators:

Lei Zheng, MD, PhD – *Executive Director of the Mays Cancer Center at the University of Texas Health San Antonio, MD Anderson Cancer Center*

J. Christine Ye, MD, MS – *MD Anderson Cancer Center*

Case presenters:

Solid Tumor case by: Xiaocao Haze Xu, MD – *University of Vermont*
Guo Cheng, MD – *Greater Baltimore Medical Center*

Hematology case by: Yuan Yao, MD – *Mayo Clinic*

Discussion Panel:

Ping Gu, MD, PhD – *Memorial Sloan Kettering Cancer Center*
Hui Chen, MD, PhD – *Duke Cancer Institute*
Lijun Dai, MD, PhD – *UPMC*
Qiwei Bill Gai, MD, PhD – *Kahlert Regional Cancer Center*
Fengting Yan, MD, PhD – *Swedish Cancer Institute*
Songchuan Guo, MD, PhD – *Rendr Care*
Yong Ji, MD, PhD – *MD Anderson Cancer Center at Cooper*
YongLi Ji, MD, PhD – *Massachusetts General Hospital*
Peter Q. Jiang, MD, PhD – *John B. Amos Cancer Center*
Pauline Lau, MD – *Dr. Lau Medical Oncology*
Mary Li, MD, PhD – *Florida Cancer Specialists*
Richard Z. Lin, MD – *Stony Brook University, Northport VA Medical Center*
Na Liu, MD – *MaineHealth Cancer Care*
Zach Liu, MD – *Pathline*
Kit Lu, MD – *UPMC Central PA*
Vincent Ma, MD – *University of Wisconsin at Madison*
Lan Mo, MD, PhD – *Maimonides Cancer Center*
Haixia Qin, MD, PhD – *Main Line HealthCare Hematology Oncology Associates*
Qian Qin, MD – *UT Southwestern*
Min Sun, MD, PhD – *UPMC Hillman Cancer Center*
Gary G. Tian, MD, PhD, FACP – *West Cancer Center*
Haiyun Wang, MD – *Cancer Care Associate of York*
Jiping Wang, MD, PhD – *Brigham and Women's Hospital*
Xiaowen Wendy Wang, MD, PhD – *The Everett Clinic*
Xiaoyang Wang, MD – *Maimonides Cancer Center*
Xia Wu, MD – *Tufts Medical Center*
Meng Xu Welliver, MD, PhD – *Mayo Clinic*
Shenhong Wu, MD, PhD – *Stony Brook University Cancer Center*
Yiqing Xu, MD, PhD – *Maimonides Medical Center*
Faye Yin, MD – *RWJ University Hospital Somerset*
Huichun Zhan, MD, MS – *Stony Brook Medicine*
Chen Zhang, MD, MS – *Rush University Medical Center*
Fengming Zhong, MD, PhD – *VANJHCS/Rutgers NJMS*
Xinhua Zhu, MD PhD – *Zucker School of Medicine at Hofstra*

6:00 – 10:00 pm **Members Only Meeting and Reception in the Gallery at The Sheraton**

Program

SUNDAY, OCTOBER 6, 2024, 8:30 AM – 12:00 PM

8:00 – 9:30 am — **On-site Registration, Exhibitors Visitation**

8:30 – 9:30 am — **Breakfast Promotional Talk** – *Sponsored by Takeda*
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade
Speaker: Abhirami Vivekanandarajah, MD – *New York Cancer & Blood Specialists*
Moderator: Zili He, MD – *Advanced Hematology Oncology PLLC*

9:30 am – 12:00 pm — **Plenary Session IV**
Session Chair: Charles Jiang, MD, MPH – *UT Southwestern Medical Center*

9:30 – 10:00 am — **Travel Grant Awardee Introduction**
Presented by: Jeffrey Pu, MD, PhD – *Harvard Medical School*
Hong Zheng, MD, PhD – *Penn State Hershey Cancer Institute*

10:00 – 10:20 am — **Break and Visit Exhibitors**

10:20 – 11:00 am — **Clinical development of CAR-T, ADC and BITE: Challenges and Solutions**
Moderator: Sen Zhuang, MD, PhD – *Johnson & Johnson*

Discussion Panel:
Chaohong Fan, MD, PhD – *CAHON*
Jing-Zhou Hou, MD, PhD – *University of Pittsburgh Medical Center Cancer Centers*
Zihai Li, MD, PhD – *The Ohio State University*
Jia Ruan, MD, PhD – *Weill Cornell Medical College*
Yucai Wang, MD, PhD – *Mayo Clinic*
Zhihong J. Wang, MD, PhD – *Virginia Commonwealth University*

11:00 am – 12:00 pm — **Bridging Clinical Trial and Research Collaboration**
Moderators: Wenru Song, MD, PhD – *Kira Pharmaceutical*
Ke Liu, MD, PhD – *Marengo Therapeutics*

Discussion Panel:
Sujuan Ba, PhD – *National Foundation for Cancer Research*
Helen Chen, MD – *National Cancer Institute Cancer Therapy Evaluation Program*
Vicky Hua Lee, MD, PhD – *Cancer Center at Jiahui International Hospital Shanghai*
Yuxia Jia, MD, PhD – *CAHON*
Raju Kucherlapati, PhD – *Harvard Medical School*
Michael Liao, MD, PhD – *Capital Medical University in Beijing*
Jianda Yuan, MD, PhD – *Merck*
Pan Zheng, MD, PhD – *OncoC4, Inc.*

12:00 pm — **Closing Remarks**
Yiwu Huang, MD, PhD – *Maimonides Medical Center*

Organizing Committee

Delong Liu, MD, PhD – *NYOF Chair, Editor-in-Chief Journal of Hematology & Oncology, New York Medical College*
Yiwu Huang, MD, PhD – *NYOF Co-chair, Maimonides Medical Center*
Liang Deng, MD, PhD – *NYOF Co-chair, Memorial Sloan Kettering Cancer Center*
Jing-Zhou Hou, MD, PhD – *University of Pittsburgh Medical Center*
Wenru Song, MD, PhD – *Kira Pharmaceuticals*
Ruirong Yuan, MD, PhD – *VA Medical Center, New Jersey*
Bo Zhao, MD – *Virginia Oncology Associates*

CAHON 2024 Lifetime Achievement Award and Outstanding Service Awards

CAHON'S 2024 LIFETIME ACHIEVEMENT AWARD WINNER

Dr. Lillian Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre.

Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016) and was Chair of the ASCO Conquer Cancer Foundation Grants Selection Committee in 2019; she served on the American Association for Cancer Research (AACR) Board of Directors for a three-year term (2017-2020). Dr. Siu is a fellow of both ASCO and AACR. Dr. Siu is the 2024-2025 President-Elect of the AACR.

Dr. Siu's major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the co-Contact PI of a phase I UM1 grant sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution's core vision to deliver precision cancer medicine.

Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010. She was awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs. In 2020, Dr. Siu was recognized for her educational efforts by the ASCO International Women Who Conquer Cancer Mentorship Award. Dr. Siu is the 2024 David A. Karnofsky Memorial Award recipient, one of the most prestigious awards from ASCO.

Dr. Siu has published over 370 peer-reviewed manuscripts, and she is currently the co-Editor-in-Chief for AACR's newest journal *Cancer Research Communications*, and is on the editorial board for Cell and Cancer Cell.

Dr. Siu delivered an excellent keynote speech at our CAHON summer symposium this year. She is a strong supporter of future CAHON-AACR collaboration to help cancer patients worldwide. This award is a well-deserved recognition of Dr. Siu's profound and enduring contributions to the field of Hematology and Oncology, and we extend our heartfelt congratulations to her.

CAHON'S 2024 OUTSTANDING SERVICE AWARD WINNERS

Recognizing significant contributions to CAHON's development and mission. This year's winners have dedicated countless hours and outstanding leadership to support CAHON activities for many years.



Bo Zhao, MD, PhD



Xinsheng (Michael) Liao, MD, PhD

Speakers

David H. Ilson, MD, PhD – Dr. David Ilson is a Professor in the Department of Medicine at Cornell University Medical College in New York, New York. He is also Attending Physician in the Department of Medicine, Gastrointestinal Oncology Service at Memorial Hospital of the Memorial Sloan Kettering Cancer Center in New York, New York. Dr. Ilson received his MD and PhD from New York University (NYU) School of Medicine in New York, New York. He completed an internship and a residency in the Department of Medicine at NYU/Bellevue Hospital Center, and he served a fellowship in Medical Oncology and Hematology at Memorial Sloan-Kettering Cancer Center.

A Fellow in the American College of Physicians and the American Society of Clinical Oncology, Dr. Ilson is an active researcher, focusing on topics including combined modality therapy in esophageal and gastric cancer. He is board-certified in Internal Medicine and Medical Oncology, and belongs to a number of medical societies, including the American College of Physicians, the American Association for Cancer Research, and the American Society for Clinical Oncology. He is a recognized international expert in the management of gastrointestinal malignances and a frequent speaker and lecturer at national and international cancer conferences. He sits on a number of editorial review boards including *Annals of Oncology* and he is Associate Editor for Gastrointestinal Cancers for the *New England Journal of Medicine Journal Watch.* He sits on the GI Cancer Committee of the Alliance for Cancer/Legacy CALGB, and he is co-chair of the Upper GI Cancers committee for NRG/Legacy RTOG. He continues to sit on the U.S. NCI Esophagogastric Cancers Task Force, and he is the former task force chair.

Yi Lin, MD, PhD – Dr. Yi Lin is a professor of medicine with joint appointment in the Division of Hematology and Experimental Pathology at Mayo Clinic, Rochester, Minnesota. Her practice is in lymphoma and myeloma. She has an NIH-funded laboratory and clinical research program in biomarkers and immunotherapy. She is the PI and co-PI of multiple clinical trials testing novel dendritic cell vaccine combination immunotherapy and CAR-T therapy. She is the medical director for the Immune Effector Cell Program at Mayo Clinic, Rochester. As the Mayo Clinic Comprehensive Cancer Center Enterprise Leader of Cancer Regenerative Biotherapeutics, she also oversees the cancer cell therapy clinical research portfolio and practices across all three Mayo sites in Minnesota, Arizona, and Florida. She also co-chairs the International Myeloma Working Group (IMWG) Novel Immunotherapy Steering Committee and co-chairs the Society for Immunotherapy of Cancer (SITC) Myeloma Cancer Immunotherapy Guideline Subcommittee.

Paul Richardson, MD – Dr. Paul Richardson is a board-certified hematologist and medical oncologist, at Dana-Farber Cancer Institute (DFCI). After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at DFCI. Dr. Richardson joined the Jerome Lipper Myeloma Center in 1999, was then appointed Clinical Director in 2001. He led the development of several first- and second-generation novel drugs, including bortezomib, lenalidomide, and later pomalidomide, for the treatment of multiple myeloma (MM). Subsequent studies have also focused on next-generation novel drugs including panobinostat and proteasome inhibitors including the orally bioavailable agent Ixazomib, followed by selinexor and most recently melflufen.

Also more recently, his clinical innovations were in the development of the monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab thereafter and the antibody drug conjugate belantamab mafodotin, followed by other immunotherapeutic strategies such as CelMoDs, including the breakthrough novel oral agent mezigdomide.

Over the last decade, his other major efforts have been focused on the development of the combination of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM) 2009 and DFCI DETERMINATION trial in newly diagnosed MM patients eligible for stem cell transplant treated with RVD, followed by the development of the quadruplet RVD plus daratumumab in the pivotal GRIFFIN study.

Dr. Richardson has published extensively, having authored or co-authored over 488 original articles and 420 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. His other major role was as Chairman of the Alliance Myeloma Committee from its founding in 2011 to the end of his maximal 10-year tenure in 2021, during which the Alliance established a key role in a series of practice changing MM clinical trials, including GRIFFIN.

Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well as an honorary

Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway in 2016. The COMY award was given in the same year and the prestigious Robert Kyle Lifetime Achievement Award

followed in 2017. The Morse Award given by DFCI for highly impactful clinical research was next in 2019 and he was named a Giant of Cancer Care in 2022. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research first in 2016 and ranked again in the top 20 in 2022 (which is within the top 1 percent of cancer research globally). Dr. Richardson was a corecipient of the inaugural James Griffin Award for translational research in 2023.

Kai He, MD, PHD – Dr. Kai He is a board-certified medical oncologist and Associate Professor with Tenure of Medicine in the Thoracic Oncology Program and Cancer Cell Therapy Program at The Ohio State University Cancer Hospital. He has expertise in the personalized care of patients with thoracic malignancies, including lung cancer, pleural mesothelioma and thymic carcinoma, based on their unique clinical, genetic and immunological characteristics.

Dr. He completed his clinical fellowship in Medical Oncology and T32 research training at Johns Hopkins Hospital, Previously, he graduated with MD degree from Peking Union Medical College and then finished his PhD training in Cell Biology at the University of Alabama at Birmingham.

As a physician-scientist in the Translational Therapeutics Program and Pelotonia Institute for Immuno-Oncology at the OSUCCC – James, his research focuses on cancer genomics and immunology, and immunotherapy including cell therapy development in lung and other solid organ cancers. He leads solid tumor cell therapy program at OSUCC. He has been involved in the studies that contributed to recent FDA approval of T cell directed immunotherapy including Tumor Infiltrating Lymphocyte (TIL) therapy in melanoma and Dll3 Bispecific in small cell lung cancer in 2024. Dr. He has co-authored over 50 publications in peer-reviewed journals, including Cancer Discovery, Journal of Clinical Oncology, Journal of Thoracic Oncology, Journal of Hematology & Oncology, Cancer Research and others. He currently serves as a member of the James Cancer Center Clinical Scientific Review Committee and Cancer Cell Therapy Committee.

Yuan Yuan, MD, PhD – Dr. Yuan Yuan is a Professor and Director of Breast Oncology at Cedars-Sinai Medical Center. She also serves as the Medical Director for Breast Cancer Research at Cedars. Her extensive translational research and clinical trial design/conduct experience in triple negative breast cancer (TNBC) render her uniquely suited to support the P01 grant in TNBC. Her research focuses on translational and clinical studies investigating novel therapeutics in metastatic breast cancer. She has a strong background in basic sciences, clinical oncology and translational medicine with specific interest in triple negative breast cancer (TNBC) chemotherapy resistance and novel therapeutics. She is currently devoting 50% of full-time effort to clinical and translational research. She has successfully developed and completed several investigator initiated breast cancer immune therapy studies including a phase I/II trial combining letrozole, palbociclib and pembrolizumab in patients with HR+ metastatic BC (NCT02778685); a phase I/II trial androgen receptor (AR) targeted therapy GTx-024 in combination with pembrolizumab in patients with metastatic AR+ TNBC (NCT02971761) and a phase IB study combining ipatasertib with carboplatin or carboplatin/paclitaxel or capecitabine/atezolizumab in patients with metastatic TNBC (NCT03853707). She served as PI for multiple CAR T trials: HER2-targeted dual switch CAR-T therapy in HER+ cancer (NCT046504751); Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*) (NCT04020575), Phase I study of ivermectin and balstilimab in patients with metastatic triple negative breast cancer (NCT05318469).

Michael J. Morris, MD – Dr. Michael Morris is a board-certified medical oncologist who specializes in treating men with prostate cancer, particularly those with metastatic or those who are at a high risk for developing metastatic disease. He is the prostate cancer section head, Division of Solid Tumor Oncology, at Memorial Sloan Kettering Cancer Center in New York, NY. As such he leads a group of experts at Memorial Sloan Kettering Cancer Center (MSK) who are dedicated to researching and treating this disease.

Dr. Morris received his medical degree from Icahn School of Medicine at Mount Sinai. He completed his residency in medicine at Columbia Presbyterian Medical Center (currently known as Columbia University Irving Medical Center) and his fellowships in oncology and hematology at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, respectively.

Much of his research focuses on drugs that can deliver radioactive molecules targeted specifically to prostate cancer cells or to the distant areas where the cancer spreads. These drugs can be used alone or in combination with other anti-cancer treatments. This research represents a team effort between medical oncologists, nuclear medicine doctors, and radiologists to bring these novel and exciting drugs to the people with prostate cancer who need them.

Dr. Morris is the medical director of the Prostate Cancer Clinical Trials Consortium, an initiative designed to increase patient access to clinical trials in the United States. He also chairs the Genitourinary Committee of the National Cancer Institute's Alliance for Clinical Trials in Oncology, which facilitates the testing of new drugs nationwide. Dr. Morris was included in Castle Connolly's *Top Doctors: New York Metro Area* in *New York* Magazine in 2013 and in 2015 through 2018.

rigel®

Committed to discovering, developing, and providing
novel therapies that significantly improve the lives of patients

Tavalisse®
(fostamatinib disodium hexahydrate) tablets

www.TAVALISSEhcp.com

GAVRETO®
pralsetinib | 100 mg capsules

www.GAVRETO-hcp.com

REZLIDHIA®
(olutasidenib) 150 mg capsules

www.REZLIDHIAhcp.com

Please see Full Prescribing Information,
including Boxed Warning, at the Rigel exhibit.

RIGL_FRN-24044 0924

SARCLISA®
(isatuximab-irfc)
Injection for IV use | 500 mg/25 mL, 100 mg/5 mL

See the latest data for **SARCLISA + Kd**

Explore the full results of the IKEMA
phase 3 trial at **sarclisahcp.com**

Kd=Kyprolis (carfilzomib) and dexamethasone

*Common mutations include L858R and exon 19 deletions.[10]

EGFR, epidermal growth factor receptor; mNSCLC, metastatic non–small cell lung cancer.

References: 1. Chiang AC, Fernandes AW, Pavilack M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. *BMC Cancer.* 2020;20(1):356. **2.** Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nat Med.* 2018;24(5):638-646. **3.** Riess JW, Gandara DR, Frampton GM, et al. Diverse *EGFR* Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. *J Thorac Oncol.* 2018;13(10):1560-1568. **4.** Arcila ME, Nafa K, Chaft JE, et al. *EGFR* exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol Cancer Ther.* 2013;12(2):220-229. **5.** Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring *EGFR* exon 20 insertions. *J Thorac Oncol.* 2013;8(2):179-184. **6.** Naidoo J, Sima C, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. *Cancer.* 2015;121(18):3212-3220. **7.** Chen D, Song Z, Cheng G. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. *Onco Targets Ther.* 2016;9:4181-4186. **8.** Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring *EGFR* exon 20 insertion mutations and common *EGFR* mutations. *Lung Cancer.* 2021;162:154-161. **9.** Bauml J, Viteri S, Minchom A, et al. Underdiagnosis of *EGFR* exon 20 insertion mutation variants: estimates from NGS-based real-world datasets. Presented at: the IASLC 2020 World Conference on Lung Cancer; January 28-31, 2021; Singapore. **10.** Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of *EGFR* exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. *PLoS One.* 2021;16(3):e0247620. **11.** Lin J, Li M, Chen S, Weng L, He Z. Efficacy and safety of first-generation EGFR-TKIs combined with chemotherapy for treatment-naive advanced non-small-cell lung cancer patients harboring sensitive *EGFR* mutations: a single-center, open-label, single-arm, phase II clinical trial. *J Inflamm Res.* 2021;14:2557-2567.

janssen Oncology

Notes


Fruzaqla®
(fruquintinib) capsules
5 mg • 1 mg
Discover the data
UZAQLA and the FRUZAQLA logo are trademarks of HUTCHMED Group Enterprises Limited, used under license.
024 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 05/24 USO-FRO-0158


LOQTORZI™
(toripalimab-tpzi)injection
LEARN MORE AT
LOQTORZIHCP.COM
© 2024 Coherus BioSciences, Inc.
All rights reserved. October 2024 US-LOQ-0028
Coherus


CABOMETYX®
(cabozantinib) tablets
60 mg | 40 mg | 20 mg
EXPLORE A
BALANCE OF DATA
Visit the Exelixis Exhibit
Booth Number: 1
SCAN TO DISCOVER MORE
CABOMETYXhcp.com
EXELIXIS®
©2024 Exelixis, Inc.
CA-3428 09/24

Chinese American Hematologist and Oncologist Network (CAHON)
555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA
Phone: 1 414-918-9890 • Fax: 1 414-276-3349
www.cahon.org

CAHON-0824-355